

WHAT IS CLAIMED IS:

Claim 1. A combination for use in the treatment of a tumor in a subject in need thereof, wherein the combination comprises:

(i) 20 mg/kg of an anti-PD-L1 antibody or an antigen-binding fragment thereof on day 1 of treatment followed by administration of 20 mg/kg of the anti-PD-L1 antibody or antigen-binding fragment thereof every 4 weeks; and

(ii) 4 mg/kg of an anti-CTLA-4 antibody or an antigen-binding fragment thereof as a single dose on day 1 of treatment,

wherein the pharmaceutical combination comprises the anti-PD-L1 antibody or antigen-binding fragment thereof, and the anti-CTLA-4 antibody or antigen-binding fragment thereof.

Claim 2. The combination according to claim 1, wherein the anti-CTLA-4 antibody or antigen-binding fragment thereof is tremelimumab.

Claim 3. The combination according to claim 1 or 2, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof is durvalumab.

Claim 4. The combination according to any one of claims 1 to 3, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof and the anti-CTLA-4 antibody or antigen-binding fragment thereof are administered to the subject simultaneously, separately, or sequentially.

Claim 5. The combination according to any one of claims 1 to 4, wherein the combination further comprises administering transarterial chemoembolization (TACE) to the subject.

Claim 6. The combination according to any one of claims 1 to 5, wherein the tumor is a hepatocellular carcinoma (HCC).

Claim 7. A combination for use in the treatment of a tumor in a subject in need thereof, wherein the combination comprises:

(i) 1500 mg of an anti-PD-L1 antibody or an antigen-binding fragment thereof on day 1 of treatment followed by administration of the anti-PD-L1 antibody or antigen-binding fragment thereof every 4 weeks; and

(ii) 300 mg of an anti-CTLA-4 antibody or an antigen-binding fragment thereof as a single dose on day 1 of treatment,

wherein the pharmaceutical combination comprises the anti-PD-L1 antibody or antigen-binding fragment thereof, and the anti-CTLA-4 antibody or antigen-binding fragment thereof.

Claim 8. The combination according to claim 7, wherein the anti-CTLA-4 antibody or antigen-binding fragment thereof is tremelimumab.

Claim 9. The combination according to claim 7 or 8, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof is durvalumab.

Claim 10. The combination according to any one of claims 7 to 9, wherein the anti-PD-L1 antibody or antigen-binding fragment thereof and the anti-CTLA-4 antibody or antigen-binding fragment thereof are administered to the subject simultaneously, separately, or sequentially.

Claim 11. The combination according to any one of claims 7 to 10, wherein the combination further comprises administering transarterial chemoembolization (TACE) to the subject.

Claim 12. The combination according to any one of claims 7 to 11, wherein the tumor is a hepatocellular carcinoma (HCC).

Claim 13. A composition for use in the treatment of a tumor in a subject in need thereof, wherein the composition comprises an anti-CTLA-4 antibody or an antigen-binding fragment thereof at a flat dose of between 650 mg to 850 mg.

Claim 14. The composition according to claim 13, wherein the dose of the anti-CTLA-4 antibody or antigen-binding fragment thereof is 750 mg.

Claim 15. The composition according to claim 13 or 14, wherein the anti-CTLA-4 antibody or antigen-binding fragment thereof is tremelimumab.

Claim 16. The composition according to any one of claims 13 to 15, wherein the anti-CTLA-4 antibody or the antigen-binding fragment thereof is administered to the subject every four weeks.

Claim 17. The composition according to any one of claims 13 to 16, wherein the anti-CTLA-4 antibody or the antigen-binding fragment thereof is to be administered to the subject every twelve weeks.

Claim 18. The composition according to any one of claims 13 to 17, wherein the combination further comprises administering transarterial chemoembolization (TACE) to the subject.

Claim 19. The composition according to any one of claims 13 to 18, wherein the tumor is a hepatocellular carcinoma (HCC).

Claim 20. The composition according to claim 13, wherein the anti-CTLA-4 antibody or antigen-binding fragment thereof is tremelimumab administered to the subject at a dose of 750 mg every four weeks for seven doses followed by administration to the subject of tremelimumab at a dose of 750 mg every twelve weeks.